Caladrius Biosciences Inc(NASDAQ:CLBS) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Mar 17, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $10.177M. Analysts estimated a revenue of $7.050M. The revenues were 44.35% above the estimates. Earnings per share were $-0.54. The reported EPS was above estimates by 32.5%. Analysts had estimated an EPS of $-0.8.
Caladrius Biosciences Inc (CLBS) shares turned negative on Wednesdays trading session with the shares closing down -0.29 points or -5.62% at a volume of 77,561. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $5.22. The peak price level was also seen at $5.22 while the days lowest was $4.8. Finally the shares closed at $4.87. The 52-week high of the shares is $8.68 while the 52-week low is $2.65. According to the latest information available, the market cap of the company is $40 M.
Several Insider Transactions has been reported to the SEC. On Feb 8, 2017, Eric Wei (director) sold 6,575 shares at $4.77 per share price.Also, On Aug 18, 2015, David J Mazzo (CEO) purchased 20,000 shares at $1.40 per share price.On Aug 13, 2015, Robert S Vaters (CFO) purchased 12,385 shares at $1.35 per share price, according to the Form-4 filing with the securities and exchange commission.
Caladrius Biosciences Inc. formerly NeoStem Inc. is a clinical-stage biopharmaceutical company. The Company’s clinical program is based on its dendritic cell and cancer cell technology. It is focused on the development of a cancer treatment designed to focus the cells responsible for tumor growth and metastasis known as cancer or tumor initiating cells (CSCs). Its lead product candidate based on this platform technology is NBS20 (targeted cancer immunotherapy) which is in Phase II trials focuses on malignant melanoma as an initial indication. Its therapeutic platforms also include ischemic repair (CD34 Cell Program) and immune modulation (T Regulatory Cell Program). Its CD34 Cell Program develops therapies designed to address diseases and conditions caused by ischemia. Its product candidate in CD34 Cell Program is NBS10 which has completed Phase I clinical trials. Under T Regulatory Cell Program the Company is developing NBS03D which is in the Phase I clinical trial stage.